行情

AVXL

AVXL

Anavex Life
NASDAQ

实时行情|Nasdaq Last Sale

3.260
+0.010
+0.31%
已收盘, 16:00 09/18 EDT
开盘
3.290
昨收
3.250
最高
3.316
最低
3.120
成交量
41.48万
成交额
--
52周最高
4.090
52周最低
1.250
市值
1.72亿
市盈率(TTM)
-5.4515
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AVXL 新闻

  • 沪指尾盘拉升 美联储宣布降息、美股先抑后扬
  • 新浪财经.1小时前
  • 印尼央行年内第三次降息 将基准利率下调25个基点
  • 新浪美股.3小时前
  • 特斯拉上海超级工厂内部照片曝光:Model 3车架已下线
  • 新浪科技.3小时前
  • 德意志银行考虑在出售顺利情况下增加坏账银行资产
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
-0.65%
制药与医学研究
-0.05%

热门股票

名称
价格
涨跌幅

AVXL 简况

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
展开

Webull提供Anavex Life Sciences Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。